Pharmaceuticals

Oculis Holding AG

Oculis Holding AG Announces First Patient Dosed in Licaminlimab Dry Eye Trial

Oculis CEO Riad Sherif Discusses Company's Journey and Three Key Medical Projects

Oculis Holding AG released FY2026 Q1 earnings on May 11 After-Market EST, actual revenue USD 261.31 K (forecast USD 197.25 K), actual EPS USD -0.6126 (forecast USD -0.5097)

Oculis Holding AG to release FY2026 Q1 earnings on May 6, 2026 (EST), forecast revenue USD 201.92 K, EPS USD -0.5193

Oculis Holding AG released FY2025 Annual Earnings on March 3 After-Market (EST), Actual Revenue USD 1.473 M (Forecast USD 1.058 M), Actual EPS USD -2.3214 (Forecast USD -2.3144)

Oculis Holding AG released FY2025 Q4 earnings on March 3 After-Market (EST), actual revenue USD 518.76 K (forecast USD 153.56 K), actual EPS USD -0.5301 (forecast USD -0.5173)

Oculis Holding AG to release FY2025 Q4 earnings on March 3 After-Market EST, forecast revenue USD 157.69 K, EPS USD -0.5312

H.C. Wainwright Maintains Buy Rating on Oculis Holding with a Target Price of $42

Oculis Holding AG Attending Ophthalmology Conference to Introduce Innovative Late-Stage Pipeline

Oculis Holding AG released FY2025 Q3 earnings on November 10 After-Market (EST), actual revenue USD 0 (forecast USD 230.15 K), actual EPS USD 0 (forecast USD -0.5233)

Oculis Holding AG released FY2025 9 Months Earnings on November 10, 2025 (EST) with actual revenue of USD 954.32K and EPS of USD -1.7909

Oculis Holding AG Participates in ICR Healthcare Conference to Discuss Late-Stage Pipeline

Oculis Holding AG to Release FY2025 Q3 Earnings on November 10 After-Market EST, Forecast Revenue USD 229.13K, EPS USD -0.521

Oculis Holding AG Raises $110 Million through Stock Sale

Gataulin Reiterates Hold Rating for Oculis Holding, Wainwright Gives Buy Rating

Serge Belanger Maintains Buy Rating for Oculis Holding and Sees Potential in OCS-05 Project

Gerberry Recommends Biotech Stocks, Oculis Holding Gets Strong Buy Rating

Oculis Holding AG released FY2025 Q2 earnings on August 21 (EST), actual revenue USD 326.33 K (forecast USD 180.25 K), actual EPS USD -0.6126 (forecast USD -0.5647)

Oculis Holding AG released FY2025 Semi-Annual Earnings on August 21 After-Market (EST), Actual Revenue: USD 649.81K, Actual EPS: USD -1.3888

Oculis Holding AG to Release FY2025 Q2 Earnings on August 21, 2025 (EST), Forecast Revenue USD 181.34 K, EPS USD -0.5681

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens GoogleAdd on GoogleZUG, Switzerland, June 09, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Executive Committee and Board of Directors. Attachmentnotification-of-managers-transaction-riad sherif-9-june-2026

StockTitan

OCULIS HOLDING AG C/WTS 06/03/2028 (TO PUR ORD)

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | OCS Stock News

Oculis Holding AG announced the randomization of the first patient in the PREDICT-1 registrational trial for Licaminlimab, a precision medicine treatment for dry eye disease (DED). This genotype-based trial targets patients with a specific TNFR1 genotype to maximize efficacy. If approved, Licaminlimab aims to transform the current trial-and-error treatment paradigm by offering a targeted solution for the significant unmet medical need in DED.

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease | OCS Stock News

The Schall Law Firm is investigating Oculis Holding AG (NASDAQ: OCS) for potential securities law violations. The inquiry focuses on whether the company issued misleading statements by claiming its Phase 3 DIAMOND trials were advancing as planned, only to announce their failure and halt FDA filing plans on May 29, 2026. Investors who suffered losses are encouraged to contact the firm to discuss their rights.

prnewswire

12:43 ETOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

Nan Fung Group Holdings sold 163,957 Oculis shares in Q1 2026 for an estimated $4.3 million, reducing its stake to 7.7% of AUM. The sale preceded Oculis's late-May 2026 Phase 3 trial failure, which caused the stock to drop ~43%. Nan Fung retains a $9.3 million position as its fourth-largest holding.

nasdaq

S&P 500

Evommune

MapLight Therapeutics

LB Pharmaceuticals

Incyte

Netflix

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Oculis Holding AG (Nasdaq: OCS) announced that its management, led by CEO Dr. Riad Sherif, will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 in Miami. The company will provide an overview of its late-stage portfolio, highlighting Privosegtor for optic neuritis and Licaminlimab for dry eye disease.

Goldman Sachs

GS Hldg R

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News

Oculis Holding AG(OCS.US)

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | OCS Stock News

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease | OCS Stock News

12:43 ETOCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News